Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...

Findings showed that pembrolizumab plus chemotherapy reduced the risk of death by 17% compared with chemotherapy alone. The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab) ...

Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old now impacted by the disease. However, despite this, knowledge about these ...

BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape Precision medicine has become a dominant theme in the treatment of biliary tract cancers (BTCs). Although prognosis ...

Nova Scotia will be the first site in the world to test a potentially groundbreaking cancer treatment. Global pharmaceutical ...

Credit: Getty Images. The sBLA is supported by data from the KEYNOTE-966 trial. The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for ...

The combination of bispecific antibody CTX-009 and chemotherapy received Fast Track Designation for advanced, previously treated biliary tract cancers. The Food and Drug Administration (FDA) has ...

Biliary tract cancers, including cholangiocarcinoma and gallbladder carcinoma, represent a heterogeneous group of malignancies with rising global incidence and persistent dismal prognoses. Research in ...

Acute cholangitis is a severe, bacterial infection of the biliary tract precipitated by an obstruction that often results in systemic inflammation and, in some cases, life‐threatening sepsis. This ...

ctDNA is a valuable prognostic biomarker for relapse in early-stage BTC, outperforming carbohydrate antigen 19-9 levels. ctDNA monitoring can detect molecular recurrence earlier than standard ...

Please provide your email address to receive an email when new articles are posted on . Researchers reported a 41% confirmed ORR among patients with HER2-positive disease. No patients with ...